NTRB · Nutriband Inc.

This disclosure signals a critical milestone in Nutriband’s product development lifecycle: the formal selection and regulatory preparation of a proprietary brand name for its lead candidate, an abuse-deterrent fentanyl patch. While not an approval or commercial launch, brand name selection is a prerequisite for FDA review under guidance on naming safety — specifically to avoid look-alike or sound-alike confusion that could cause medication errors. The engagement of Brand Institute, a leader with documented FDA naming success (including majority of approved abuse-deterrent opioid names), underscores the strategic importance of this step and de-risks the naming pathway. The disclosed $80–200 million peak U.S. sales estimate reflects management’s assessment of unmet need and market opportunity, though no clinical, regulatory, or commercial timelines are provided. Importantly, the filing contains no financial results, forward guidance, financing terms, or executive changes — limiting near-term operational impact. Materiality is assessed as MEDIUM because brand name finalization accelerates the path toward regulatory submission but does not confirm timing, approval likelihood, or revenue generation.